Orphazyme not seeking fresh capital despite reduced cash position

After receiving a rejection from the US FDA on Friday, Orphazyme has shaved DKK 300m off its annual cash flow guidance. CEO rejects having plans to chase fresh capital.

Orphazyme CEO Christophe Bourdon | Photo: Orphazyme / PR

Although Orphazyme will be missing out on a considerable amount of money after its application to the US Food and Drug Administration (FDA) was rejected on Friday, the CEO Christophe Bourdon tells MedWatch that he does not predict that the firm will be seeking extra funds in a capital hunt.

Danske Markets Senior Analyst Thomas Bowers has previously pointed out that an FDA rejection letter might lead to the company going on the hunt for capital.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs